Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2018-12-10 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Presentation at BMO Healthcare Conference
Regulatory Filings Classification · 98% confidence The document is a short announcement (under 5,000 characters) issued via the Regulatory News Service (RNS) regarding a company's upcoming participation in an investor conference. It does not contain the full presentation materials themselves, but rather serves as a notification of the event. Therefore, it falls under the category of a general regulatory announcement.
2018-12-10 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and relates to a proposed merger between Mereo BioPharma Group plc and OncoMed Pharmaceuticals, Inc. It includes detailed information about the merger terms, management and governance changes, strategic rationale, and pipeline overview. The presence of Rule 425 filing and detailed merger-related disclosures indicates this is a merger communication document. It is not a proxy statement or a definitive merger agreement but a communication related to the merger proposal. Therefore, the document fits the category of Merger & Acquisition filings, which include Form 425 merger communications.
2018-12-06 English
425 Filing
Merger & Acquisition Classification · 100% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and relates to a proposed merger between Mereo BioPharma Group plc and OncoMed Pharmaceuticals, Inc. It contains detailed information about the merger agreement, merger consideration, conditions to the merger, and other terms of the merger agreement. The document references the filing of a proxy statement/prospectus on Form F-4 with the SEC, which is typical for merger communications. The presence of forward-looking statements and detailed merger terms indicates this is a merger communication rather than a proxy solicitation or a simple announcement. Rule 425 filings are specifically used for merger communications and disclosures related to tender offers or mergers. Therefore, this document fits the category of Merger & Acquisition filings (MA).
2018-12-06 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a detailed announcement filed pursuant to Rule 425 under the Securities Act of 1933, relating to a proposed merger between Mereo BioPharma Group plc and OncoMed Pharmaceuticals, Inc. It includes extensive information about the terms of the transaction, the combined business strategy, share exchange ratios, contingent value rights, board changes, and operational plans post-merger. The document also references a conference call and webcast to discuss the combination. The presence of detailed merger terms, share issuance plans, and the Rule 425 filing strongly indicate this is a merger-related filing. Rule 425 filings are typically used for merger communications and tender offer disclosures. Therefore, the document fits best under the category of Merger & Acquisition (MA) filings rather than a general announcement or proxy solicitation. The document length and content confirm it is not a brief announcement or a proxy statement but a substantive merger communication.
2018-12-06 English
425 Filing
Call Transcript Classification · 100% confidence The document is a transcript of a conference call discussing a proposed merger between Mereo BioPharma Group plc and OncoMed Pharmaceuticals, Inc. It includes detailed discussion of the merger terms, strategic rationale, management and board changes, and future plans. The filing is identified as being pursuant to Rule 425 under the Securities Act of 1933, which relates to merger communications. The content is a full transcript of the call, including presentations and Q&A, not just a brief announcement or press release. Therefore, this document fits the category of a Call Transcript (CT).
2018-12-06 English
Proposed combination of Mereo and OncoMed
M&A Activity Classification · 100% confidence The document is a formal announcement regarding a proposed merger and acquisition (combination) between Mereo BioPharma Group plc and OncoMed Pharmaceuticals. It details the transaction structure, exchange ratios, board changes, and future integration plans. This falls squarely under the definition of M&A activity (TAR).
2018-12-05 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.